Trajectory of bodyweight and skeletal muscle mass in patients treated with nintedanib for idiopathic pulmonary fibrosis

Trajectory of bodyweight and skeletal muscle mass in patients treated with nintedanib for idiopathic pulmonary fibrosis

Summary: Background and Aims: Nintedanib is currently a therapeutic option for idiopathic pulmonary fibrosis (IPF). Weight loss is a common complication of IPF and a side effect of nintedanib, inducing loss of skeletal muscle mass and musculoskeletal dysfunction. Thus far, few clinical studies have...

Full description

Bibliographic Details
Main Authors: Hiromi Tomioka, Takashi Fujikawa
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Clinical Nutrition Open Science
Subjects:
Idiopathic pulmonary fibrosis
Nintedanib
Adverse events
Weight loss
Skeletal muscle mass
Online Access:http://www.sciencedirect.com/science/article/pii/S2667268524000834

Internet

http://www.sciencedirect.com/science/article/pii/S2667268524000834

Similar Items